|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
29,260,000 |
Market
Cap: |
233.79(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.06 - $7.25 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile XBiotech is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases. Co. has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. An area of medical focus for Co. are therapies that block a substance naturally produced by body, known as interleukin-1 alpha, that mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting and inflammation. Co.'s product development includes: Natrunix program, which is for the indication of pancreatic cancer and rheumatoid arthritis, and Hutrukin program, which is for the indication of stroke.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hu Angela |
Principle Financial OfficerOff |
|
2023-02-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,500 |
|
50% |
|
Mckenzie W Thorpe |
Director |
|
2021-12-16 |
4 |
D |
$11.71 |
$2,500,003 |
D/D |
(213,493) |
2,597,471 |
|
- |
|
Mckenzie W Thorpe |
Director |
|
2021-12-16 |
4 |
OE |
$10.00 |
$2,500,000 |
D/D |
250,000 |
2,810,964 |
|
- |
|
Simard John |
Chief Executive Officer |
|
2021-10-18 |
4 |
S |
$13.07 |
$431,254 |
D/D |
(33,000) |
3,823,166 |
|
27% |
|
Simard John |
Chief Executive Officer |
|
2021-10-15 |
4 |
S |
$13.32 |
$226,471 |
D/D |
(17,000) |
3,856,166 |
|
25% |
|
Simard John |
Chief Executive Officer |
|
2021-10-14 |
4 |
S |
$12.90 |
$272,523 |
D/D |
(21,125) |
3,873,166 |
|
25% |
|
Simard John |
Chief Executive Officer |
|
2021-10-13 |
4 |
S |
$12.83 |
$139,526 |
D/D |
(10,875) |
3,962,452 |
|
24% |
|
Simard John |
Chief Executive Officer |
|
2021-10-12 |
4 |
S |
$12.77 |
$229,939 |
D/D |
(18,000) |
3,973,166 |
|
26% |
|
Simard John |
Chief Executive Officer |
|
2021-10-07 |
4 |
S |
$12.45 |
$489,111 |
D/D |
(39,286) |
3,923,166 |
|
23% |
|
Simard John |
Chief Executive Officer |
|
2021-10-06 |
4 |
S |
$12.53 |
$134,259 |
D/D |
(10,714) |
3,962,452 |
|
19% |
|
Simard John |
Chief Executive Officer |
|
2021-10-05 |
4 |
S |
$12.66 |
$180,058 |
D/D |
(14,218) |
3,973,166 |
|
17% |
|
Simard John |
Chief Executive Officer |
|
2021-10-04 |
4 |
S |
$13.08 |
$309,864 |
D/D |
(23,681) |
3,987,384 |
|
23% |
|
Simard John |
Chief Executive Officer |
|
2021-10-01 |
4 |
S |
$13.23 |
$260,488 |
D/D |
(19,684) |
4,011,065 |
|
23% |
|
Simard John |
Chief Executive Officer |
|
2021-09-30 |
4 |
S |
$13.07 |
$242,464 |
D/D |
(18,558) |
4,030,749 |
|
22% |
|
Simard John |
Chief Executive Officer |
|
2021-09-29 |
4 |
S |
$13.41 |
$219,801 |
D/D |
(16,396) |
4,049,307 |
|
21% |
|
Simard John |
Chief Executive Officer |
|
2021-09-28 |
4 |
S |
$14.27 |
$89,364 |
D/D |
(6,263) |
4,065,703 |
|
26% |
|
Simard John |
Chief Executive Officer |
|
2021-09-27 |
4 |
S |
$14.81 |
$442,790 |
D/D |
(29,890) |
4,071,966 |
|
32% |
|
Simard John |
Chief Executive Officer |
|
2021-09-24 |
4 |
S |
$14.49 |
$165,409 |
D/D |
(11,418) |
4,101,856 |
|
32% |
|
Simard John |
Chief Executive Officer |
|
2021-09-23 |
4 |
S |
$14.68 |
$145,220 |
D/D |
(9,892) |
4,113,274 |
|
33% |
|
Simard John |
Chief Executive Officer |
|
2021-09-22 |
4 |
S |
$15.14 |
$297,757 |
D/D |
(19,669) |
4,123,166 |
|
32% |
|
Simard John |
Chief Executive Officer |
|
2021-09-21 |
4 |
S |
$15.24 |
$256,913 |
D/D |
(16,860) |
4,142,835 |
|
31% |
|
Simard John |
Chief Executive Officer |
|
2021-09-20 |
4 |
S |
$15.06 |
$202,914 |
D/D |
(13,471) |
4,159,695 |
|
29% |
|
Simard John |
Chief Executive Officer |
|
2021-07-14 |
4 |
S |
$18.15 |
$907,350 |
D/D |
(50,000) |
4,173,166 |
|
28% |
|
Macadam Donald H. |
Director |
|
2021-07-09 |
4 |
OE |
$4.40 |
$44,000 |
D/D |
10,000 |
10,000 |
|
- |
|
Libby Peter |
Director |
|
2021-07-09 |
4 |
OE |
$7.76 |
$194,000 |
D/D |
25,000 |
25,000 |
|
- |
|
124 Records found
|
|
Page 1 of 5 |
|
|